Group 1 - Core viewpoint: 基石药业-B (02616) shares rose over 4%, currently trading at 5.82 HKD with a transaction volume of 24.98 million HKD, following the announcement of its drug being included in the national medical insurance list [1] - The drug, 普吉华 (普拉替尼胶囊, 100 mg), will be officially included in the latest version of the National Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug List by the National Healthcare Security Administration of China, effective from January 1, 2026 [1] - On December 4, non-executive director 胡正国 increased his stake in 基石药业 by purchasing 1 million shares at a price of 5.7546 HKD per share, totaling 5.7546 million HKD, raising his total holdings to 3.471 million shares, which represents 0.24% of the company [1]
港股异动 基石药业-B(02616)现涨超4% 普吉华获纳入国家医保目录 非执行董事近日增持100万股